Form 4: Nurix Therapeutics CFO Hans van Houte Sells 20,000 Shares

Hans van Houte, CFO of Nurix Therapeutics, sold 20,000 shares of common stock at an average price of $20.0108 on June 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On June 20, 2024, Hans van Houte, the Chief Financial Officer of Nurix Therapeutics, sold 20,000 shares of the company's common stock.
• The sale was executed at a weighted average price of $20.0108 per share.
• The prices ranged from $20.00 to $20.06.
• The transaction was conducted under a pre-existing Rule 10b5-1 trading plan.
• Following the transaction, van Houte directly owns 48,333 shares of Nurix Therapeutics.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale by an executive under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Insider sales are a common occurrence in publicly traded companies. Investors often monitor these transactions for signals about management's confidence in the company's future prospects. However, sales under pre-arranged trading plans are generally viewed as less informative, as they are often implemented for personal financial planning reasons.

Comparison to Industry Standards

• It's difficult to compare this transaction directly to industry standards without knowing the specifics of Hans van Houte's compensation package and overall holdings.
• However, insider sales are a regular part of executive compensation, particularly in the biotech industry where stock options and equity grants are common.
• Comparable companies like Arvinas, Inc. and Relay Therapeutics, Inc. also see regular Form 4 filings related to insider transactions.

Key Dates